Oncology outcomes
Does socioeconomic status change cancer survival?
Open access · cc by · source: Europe PMC
In Norwegian women, lower education and income predicted worse cancer survival until stage and smoking were accounted for.
Study at a glance
- Design
- Cohort — NOWAC; education and household income vs cancer survival with stage and smoking adjustment
- N
- N=3849 · 3,849 incident invasive cancers with SES data from a 91,814-woman study population
- Population
- Norwegian women with incident primary invasive cancer in NOWAC
- Outcome
- Cancer survival by education and household income
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
An overall negative SES–survival gradient was present. Stage contribution was inconsistent, smoking was important, and after adjusting for stage and smoking the education and income differences became non-significant.
Methodology
Using the Norwegian Women and Cancer cohort, investigators related education and household income to cancer survival and tested whether stage and pre-diagnosis smoking explained socioeconomic gradients.
Limitations
Observational findings in Norwegian women cannot isolate residual treatment inequities after smoking and stage adjustment.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Multiple studies in this library examine oncology outcomes with empirical patient or population outcomes rather than opinion alone.
Evidence for the claim as stated.
An overall negative SES–survival gradient was present. Stage contribution was inconsistent, smoking was important, and after adjusting for stage and smoking the education and income differences became non-significant.
Evidence for the claim as stated.
Effect sizes and settings differ across oncology outcomes studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Evidence for the claim as stated.
Protective lifestyle HRs and harmful drug HRs are not interchangeable clinical instructions. Diet-quality HRs around 0.74–0.78 and HLI HRs of 0.67–0.77 do not prove that prescribing a diet would prevent depression or diabetes, while extra falls on named antidepressants may mark who is prescribed them rather than a pure drug effect. Norwegian cancer-survival SES gradients even became non-significant after stage and smoking were in the model.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Effect sizes and settings differ across oncology outcomes studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- Supports · ANXA1 in breast cancer prognosis
- Supports · Propofol vs sevoflurane and breast cancer survival
Protective lifestyle HRs and harmful drug HRs are not interchangeable clinical instructions. Diet-quality HRs around 0.74–0.78 and HLI HRs of 0.67–0.77 do not prove that prescribing a diet would prevent depression or diabetes, while extra falls on named antidepressants may mark who is prescribed them rather than a pure drug effect. Norwegian cancer-survival SES gradients even became non-significant after stage and smoking were in the model.
- Supports · Diet quality and depression risk
- Supports · Healthy lifestyle and multimorbidity risk
- Supports · Antidepressant adverse events cohort
Related papers in this topic
Same topic cluster — not a recommendation engine.
- miR-122 exosomes from fat stem cells sensitize HCC models to chemo
- A 22-gene classifier flags early metastasis after prostatectomy
- HDAC2 IHC tracks shorter PSA relapse in prostate cancer
- Five integrated genomic subgroups track prostate-cancer relapse risk
- Higher tumour EZH2 tracks portal-vein invasion in HCC